New yellow fever vaccine shows promise in early trial
NCT ID NCT04142086
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 1 study tested a new yellow fever vaccine (vYF) in 73 healthy adults aged 18 to 60. The goal was to check the vaccine's safety and how well it triggers an immune response at three different doses. Participants were monitored for side effects and antibody levels over six months. The results will help decide if larger studies are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- yellow fever vaccine (vYF)
- What this could lead to
- If successful, this could lead to a new, safer yellow fever vaccine that is easier to produce.
- What could go wrong
- This is an early Phase 1 trial with only 73 healthy adults, so results may not apply to everyone. The vaccine may not trigger a strong enough immune response or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for YELLOW FEVER (HEALTHY VOLUNTEERS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational Site Number 8400001
Silver Spring, Maryland, 20910, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.